INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES QUANTITATIVE ESTIMATION OF RAFOXANIDE IN POWDER FOR SUSPENSION BY SPECTROPHOTOMETRIC METHODS

ABSTRACT Two simple, rapid, cost effective spectrophotometric methods have been developed for the determination of Rafoxanide in its bulk form as well as pharmaceutical dosage form. Method M 1 is based on measurement of absorbance at its absorption maximum at about 280nm against a methanol solution as a blank. Method M 2 is based on oxidation of the drug followed by complexation with 2,2'-bipyridyl reagent to give blood red colored coordination complex which has shown maximum absorbance at the maximum at about 520 nm against its reagent blank. These methods were found linear within the concentration range of 5-25μg/ml and 4-28μg/ml for Method M 1 and Method M 2 respectively. The proposed methods show correlation coefficient of >0.999 for the given concentration ranges. These methods were validated according to ICH guidelines and the result of estimation of marketed powder formulation was found to be 99.50% and 99.77% for Method M 1 and Method M 2 respectively with their %RSD of precision less than 2

Development of RP-HPLC Method for the Simultaneous Quantitation of Levamisole and Albendazole: Application to Assay Validation

A reverse phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for simultaneous estimation of levamisole and albendazole in drug substance and in its combinational dosage form. The analysis was carried out using Inertsil ODS C18 (4.6 x 150 mm, 5 μm) column, and the separation was carried out using a mobile phase containing a buffer of pH 3.5 and acetonitrile (70:30 v/v) pumped at a flow rate of 1.0 mL/min with variable wavelength UV-detection at 224 nm. Both the drugs were well resolved in the stationary phase and the retention times were 2.350 min and 4.055 for levamisole and albendazole, respectively. The method was validated and shown to be linear in the concentration range of 15-45μg/ml and 40-120μg/ml for levamisole and albendazole, respectively. The limit of detection (LOD) and limit of quantification (LOQ) were determined based on standard deviation of the y-intercept and the slope of the calibration curve. LOD and LOQ values were 2.08μg/ml and 6.03μg/ml for levamisole and 3.15μg/ml and 10.40μg/ml for albendazole, respectively. The accuracy of the method was assessed by adding known amount of standard solution (75 %, 100 %, and 125% of the sample concentration) to the preanalyzed sample solution of 100% concentration. All the samples were prepared and analyzed in triplicate. The percentage mean recovery by standard addition experiments of levamisole and albendazole is 99.66% and 98.73%, respectively

A VALIDATED RP-HPLC METHOD FOR THE DETERMINATION OF SPARFLOXACIN IN BULK AND PHARMACEUTICAL DOSAGE FORM

Objective: To develop a simple, accurate, precise and selective isocratic reversed phase-high performance liquid chromatography (RP-HPLC) method was developed for the quantitative estimation of Sparfloxacin in pharmaceutical formulations.Experimental:  RP-HPLC method was developed by using Welchrom C18 Column with 250 mm x 4.6 mm i.d and 5µm particle size, SHIMADZU LC-20AT Prominence liquid chromatograph. The mobile phase used is phosphate buffer (pH-3.0): acetonitrile (70:30percent v/v) with a flow rate of 1mL/min.  The eluent was monitored by UV detection at 291nm using SHIMADZU SPD-20A prominence UV-Vis detector.Results: The retention time of Sparfloxacin found to be 5.499 min. The method retains linearity in the range of 2-10µg/mL with correlation coefficient 0.9999. The mean recovery of sparfloxacin was 99.702percent to 100.456percent. The LOD and LOQ of the drug were found to be 0.186 µg/mL and 0.558 µg/mL respectively.  Conclusion: The proposed method can be successfully used for routine determination of sparfloxacin in pharmaceutical formulations. KEY WORDS:  Sparfloxacin, Isocratic RP-HPLC, Correlation coefficient , Method Validation